Logo
x

Search category

Subscribe Now

Out-Licensing Agreement

CStone Signs an Out-Licensing Agreement with EQRx for Sugemalimab and CS1003

CStone Signs an Out-Licensing Agreement with EQRx for Sugemalimab and CS1003

  • October 27, 2020
Merck Signs an Out-Licensing Agreement with Novartis for M6495 (Anti-ADAMTS5 Nanobody) for Osteoarthritis

Merck Signs an Out-Licensing Agreement with Novartis for M6495 (Anti-ADAMTS5 Nanobody) for Osteoarthritis

  • October 7, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.